Infliximab for maintenance of medically‐induced remission in Crohn's disease
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012609.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 19 febrero 2024see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Salud digestiva
- Copyright:
-
- Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Morris Gordon: secured funding, designed and developed, screened, extracted, resolved conflicts, assessed certainty, contributed to writing and editing, advised on, approved the final version prior to submission, and is a guarantor of the review.
Vassiliki Sinopoulou: assessed certainty, contributed to writing and editing, advised on, and approved the final version prior to submission.
Arni Sarian: screened, extracted, assessed certainty, contributed to writing and editing, and approved the final version prior to submission.
Anthony K Akobeng: advised on, and approved the final version prior to submission.
Gordon William Moran: screened, extracted, assessed certainty, contributed to writing and editing, and approved the final version prior to submission.
Sources of support
Internal sources
-
University of Central Lancashire, UK
Internal funding for MG and VS comes from their salary for their employment by the University of Central Lancashire.
External sources
-
NIHR grant, UK
This review was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR132748) Programme Grant Scheme. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Declarations of interest
Morris Gordon: Nothing to declare
Vassiliki Sinopoulou: Nothing to declare
Arni Sarian: Nothing to declare
Anthony K Akobeng: Nothing to declare
Gordon William Moran: AbbVie (Independent Contractor ‐ Consultant), Janssen Biotech (Grant / Contract), AstraZeneca AB (Grant / Contract)
AA and MG are Cochrane editors. They were not involved in the editorial process.
Acknowledgements
This review was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR132748) Programme Grant Scheme. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Editorial and peer‐reviewer contributions
Cochrane Gut supported the authors in the development of this review.
The following people conducted the editorial process for this article:
-
Sign‐off Editor (final editorial decision): Grigoris Leontiadis, Co‐ordinating Editor of the Cochrane Gut Group;
-
Managing Editor (provided editorial guidance to authors, edited the article): Helen Wakeford, Central Editoral Service;
-
Information Scientist: Dr Farhad Shokraneh (Systematic Review Consultants LTD) ran the searches in August 2021 and updated them in June 2023.
-
Editorial Assistant (selected peer reviewers, collated comments, conducted editorial policy checks and supported editorial team): Sara Hales‐Brittain, Central Editorial Service;
-
Copy Editor (copy editing and production): Anne Lethaby, Cochrane Central Production Service
-
Peer‐reviewers (provided comments and recommended an editorial decision): Mark A. Ainsworth, Department of Medical Gastroenterology, Odense University Hospital (clinical/content review), Eugenia Shmidt, MD, University of Minnesota (clinical/content review), George Lillington, Consumer Reviewer, Cochrane (consumer review), Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review), Steve McDonald, Cochrane Australia (search review)
Version history
| Published | Title | Stage | Authors | Version |
| 2024 Feb 19 | Infliximab for maintenance of medically‐induced remission in Crohn's disease | Review | Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Arni Sarian, Gordon William Moran | |
| 2017 Mar 22 | Infliximab for maintenance of remission in Crohn's disease | Protocol | Robert Battat, Navjot Deol, Tran M Nguyen, Claire E Parker, Reena Khanna, Brian G Feagan, Vipul Jairath | |
Differences between protocol and review
A protocol for this review was published in 2017 by a different author team (Battat 2017). We have updated the methods based on more recent Cochrane guidance, and we have amended the outcomes and planned analyses, before commencement of the review. We have also updated the background section.
Any planned analyses which are reported in the methods section but not in the results, could not be performed due to lack of sufficient data.
We changed the title of the review to 'Infliximab for maintenance of medically‐induced remission in Crohn's disease' from the protocol title 'Infliximab for maintenance of remission in Crohn's disease' to clarify that surgical interventions were not considered for this review.
